ProCE Banner Activity

CE

Understanding CAR T-Cell Therapy: Guidance for Current Clinic and Future Directions

Multimedia
Watch this interactive webcast of a live CCO webinar tailored to managed care and specialty pharmacy professionals to gain expert perspectives on pharmacy fundamentals of CAR T-cell therapy.

Pharmacists: 1.00 contact hour (0.1 CEUs)

Released: September 28, 2021

Expiration: September 27, 2022

No longer available for credit.

Share

Faculty

Craig Freyer

Craig Freyer, PharmD, BCOP

Clinical Pharmacy Specialist
Hematology/Oncology, Stem Cell Transplant, and Cellular Therapy
Department of Pharmacy
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania

Zahra Mahmoudjafari

Zahra Mahmoudjafari, PharmD, BCOP, DPLA

Clinical Pharmacy Manager, Blood and Marrow Transplant Program
Division of Hematological Malignancies and Cellular Therapeutics
PGY2 Oncology Residency Program Director
The University of Kansas Cancer Center
Westwood, Kansas

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Bristol Myers Squibb

Target Audience

This educational program is intended for managed care and specialty pharmacy professionals and other healthcare providers who care for patients with hematologic malignancies.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Review the biologic principles underlying CAR T-cell therapy, structure, and function of the CAR and the mechanism of action of CAR T-cells
  • Identify characteristics of patients who are candidates appropriate for treatment with CAR T-cell therapy
  • Provide safe and effective patient care services through an understanding of the clinical trial data on CAR T-cell–based therapies used to treat patients with leukemia or B-cell lymphomas, myeloma, or chronic lymphocytic leukemia

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Craig Freyer, PharmD, BCOP

Clinical Pharmacy Specialist
Hematology/Oncology, Stem Cell Transplant, and Cellular Therapy
Department of Pharmacy
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania

Craig W. Freyer, PharmD, has disclosed that he has received consulting fees from Astellas, EUSA Pharma, Incyte, and Servier and fees for non-CME/CE services from Astellas.

Zahra Mahmoudjafari, PharmD, BCOP, DPLA

Clinical Pharmacy Manager, Blood and Marrow Transplant Program
Division of Hematological Malignancies and Cellular Therapeutics
PGY2 Oncology Residency Program Director
The University of Kansas Cancer Center
Westwood, Kansas

Zahra Mahmoudjafari, PharmD, BCOP, DPLA, has disclosed that she has received consulting fees from Bristol-Myers Squibb, Coherus, GlaxoSmithKline, Incyte, Medexus, Merck, Novartis, and Omeros.

Staff Disclosure

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Ryan P. Topping, PhD

Associate Managing Editor

Ryan P. Topping, PhD, has no relevant conflicts of interest to report

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit

Credit Designation

CCO designates this continuing education activity for 1.0 contact hours (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-21-190-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 28, 2021, through September 27, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge, competence, and performance of managed care and specialty pharmacy professionals and other healthcare professionals to confidently and competently integrate CAR T-cell therapy into their clinical practices.